Search results
Q1 2024 XP Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoI want to highlight this as an important differentiator that sets us apart in the market. Currently, we are not aware of any other player implementing a strategy similar to ours on the same ...
Macy's (M) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoOur private brand apparel initiative is moving forward as planned. We have completed the majority of our brand exits and reimagined and launched several...
Earnings call: BiomX reports Q1 2024 results, optimistic on phage therapies By Investing.com
Investing.com· 3 days agoBiomX Inc. (NYSE: NYSE:PHGE), a biotechnology company specializing in phage-based therapies, has...
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Ross...
Benzinga· 14 hours agoShares of Ross Stores, Inc. ROST rose sharply in today's pre-market trading after the company reported better-than-expected earnings for its first quarter and increased its ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 1 day agoKronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 1 day agoMultiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as either a monotherapy or in combination with
Lipella Pharmaceuticals advances hemorrhagic cystitis treatment By Investing.com
Investing.com· 3 days agoLipella Pharmaceuticals Inc. (NASDAQ: LIPO), a clinical-stage biotech firm, announced today its...
Domo Inc (DOMO) Q1 2025 Earnings Call Transcript Highlights: Rev
Guru Focus· 2 days agoTotal Revenue: $80.1 million, a year-over-year increase of 1%.Subscription Revenue: 90% of total revenue, also grew at 1% year over year.Q1 Billings: $65.5 mil
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term...
Digital Journal· 1 day agoPoster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable tolerability sets stage for Part 3 (dose optimization) of
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Morningstar· 2 days agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines ...
